申请人:Kissei Pharmaceutical Co., Ltd.
公开号:EP2474530A1
公开(公告)日:2012-07-11
A compound represented by the general formula (I) of the present invention, which has an EP1 receptor antagonism:
[wherein A represents a benzene ring or the like; Y represents a C1-6 alkylene group or the like; RN represents a hydrogen atom or a C1-6 alkyl group; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like;R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
由本发明通式(I)代表的化合物,具有 EP1 受体拮抗作用:
[其中 A 代表苯环或类似物;Y 代表 C1-6 亚烷基或类似物;RN 代表氢原子或 C1-6 烷基;R1 代表氢原子、C1-6 烷基或类似物;R2 代表可能具有取代基的苯基、可能具有取代基的 5 元芳香杂环基团、可能具有取代基的 6 元芳香杂环基团或类似基团;R3 代表卤素原子、C1-6 烷氧基或类似基团;R4 代表氢原子或类似基团;以及 R5 代表氢原子或类似基团]或其药学上可接受的盐。此外,本发明的化合物(I)可用作治疗或预防 LUTS,特别是 OABs 的各种症状的制剂。